Halozyme Therapeutics Stock Volatility
| HALO Stock | USD 45.70 0.06 0.13% |
Halozyme Therapeutics holds Efficiency (Sharpe) Ratio of -0.11, which attests that the entity had a -0.11% return per unit of risk over the last 3 months. Halozyme Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Halozyme Therapeutics' Risk Adjusted Performance of (0.07), standard deviation of 3.65, and Market Risk Adjusted Performance of (0.24) to validate the risk estimate we provide. Key indicators related to Halozyme Therapeutics' volatility include:
30 Days Market Risk | Chance Of Distress | 30 Days Economic Sensitivity |
Halozyme Therapeutics Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of Halozyme daily returns, and it is calculated using variance and standard deviation. We also use Halozyme's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of Halozyme Therapeutics volatility.
Halozyme |
ESG Sustainability
While most ESG disclosures are voluntary, Halozyme Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Halozyme Therapeutics' managers and investors.Environmental | Governance | Social |
Since volatility provides investors with entry points to take advantage of stock prices, companies, such as Halozyme Therapeutics can benefit from it. Downward market volatility can be a perfect environment for investors who play the long game. Here, they may decide to buy additional stocks of Halozyme Therapeutics at lower prices. For example, an investor can purchase Halozyme stock that has halved in price over a short period. This will lower your average cost per share, thereby improving your portfolio's performance when the markets normalize. Similarly, when the prices of Halozyme Therapeutics' stock rises, investors can sell out and invest the proceeds in other equities with better opportunities. Investing when markets are volatile with better valuations will accord both investors and companies the opportunity to generate better long-term returns.
Moving together with Halozyme Stock
| 0.61 | VRAX | Virax Biolabs Group | PairCorr |
| 0.81 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.64 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Halozyme Stock
| 0.63 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.54 | PRAX | Praxis Precision Med | PairCorr |
| 0.51 | ALVO | Alvotech | PairCorr |
| 0.49 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.43 | VRDN | Viridian Therapeutics | PairCorr |
| 0.4 | BMEA | Biomea Fusion | PairCorr |
| 0.39 | NTRB | Nutriband | PairCorr |
| 0.33 | AKRO | Akero Therapeutics | PairCorr |
Halozyme Therapeutics Market Sensitivity And Downside Risk
Halozyme Therapeutics' beta coefficient measures the volatility of Halozyme stock compared to the systematic risk of the entire market represented by your selected benchmark. In mathematical terms, beta represents the slope of the line through a regression of data points where each of these points represents Halozyme stock's returns against your selected market. In other words, Halozyme Therapeutics's beta of 1.51 provides an investor with an approximation of how much risk Halozyme Therapeutics stock can potentially add to one of your existing portfolios. Halozyme Therapeutics exhibits very low volatility with skewness of -0.73 and kurtosis of 6.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Halozyme Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Halozyme Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.
3 Months Beta |Analyze Halozyme Therapeutics Demand TrendCheck current 90 days Halozyme Therapeutics correlation with market (Dow Jones Industrial)Halozyme Beta |
Halozyme standard deviation measures the daily dispersion of prices over your selected time horizon relative to its mean. A typical volatile entity has a high standard deviation, while the deviation of a stable instrument is usually low. As a downside, the standard deviation calculates all uncertainty as risk, even when it is in your favor, such as above-average returns.
Standard Deviation | 3.72 |
It is essential to understand the difference between upside risk (as represented by Halozyme Therapeutics's standard deviation) and the downside risk, which can be measured by semi-deviation or downside deviation of Halozyme Therapeutics' daily returns or price. Since the actual investment returns on holding a position in halozyme stock tend to have a non-normal distribution, there will be different probabilities for losses than for gains. The likelihood of losses is reflected in the downside risk of an investment in Halozyme Therapeutics.
Halozyme Therapeutics Stock Volatility Analysis
Volatility refers to the frequency at which Halozyme Therapeutics stock price increases or decreases within a specified period. These fluctuations usually indicate the level of risk that's associated with Halozyme Therapeutics' price changes. Investors will then calculate the volatility of Halozyme Therapeutics' stock to predict their future moves. A stock that has erratic price changes quickly hits new highs, and lows are considered highly volatile. A stock with relatively stable price changes has low volatility. A highly volatile stock is riskier, but the risk cuts both ways. Investing in highly volatile security can either be highly successful, or you may experience significant failure. There are two main types of Halozyme Therapeutics' volatility:
Historical Volatility
This type of stock volatility measures Halozyme Therapeutics' fluctuations based on previous trends. It's commonly used to predict Halozyme Therapeutics' future behavior based on its past. However, it cannot conclusively determine the future direction of the stock.Implied Volatility
This type of volatility provides a positive outlook on future price fluctuations for Halozyme Therapeutics' current market price. This means that the stock will return to its initially predicted market price. This type of volatility can be derived from derivative instruments written on Halozyme Therapeutics' to be redeemed at a future date.Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Halozyme Therapeutics Average Price is the average of the sum of open, high, low and close daily prices of a bar. It can be used to smooth an indicator that normally takes just the closing price as input.
Halozyme Therapeutics Projected Return Density Against Market
Given the investment horizon of 90 days the stock has the beta coefficient of 1.5101 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Halozyme Therapeutics will likely underperform.Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Halozyme Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Halozyme Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Halozyme stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Halozyme Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Predicted Return Density |
| Returns |
What Drives a Halozyme Therapeutics Price Volatility?
Several factors can influence a stock's market volatility:Industry
Specific events can influence volatility within a particular industry. For instance, a significant weather upheaval in a crucial oil-production site may cause oil prices to increase in the oil sector. The direct result will be the rise in the stock price of oil distribution companies. Similarly, any government regulation in a specific industry could negatively influence stock prices due to increased regulations on compliance that may impact the company's future earnings and growth.Political and Economic environment
When governments make significant decisions regarding trade agreements, policies, and legislation regarding specific industries, they will influence stock prices. Everything from speeches to elections may influence investors, who can directly influence the stock prices in any particular industry. The prevailing economic situation also plays a significant role in stock prices. When the economy is doing well, investors will have a positive reaction and hence, better stock prices and vice versa.The Company's Performance
Sometimes volatility will only affect an individual company. For example, a revolutionary product launch or strong earnings report may attract many investors to purchase the company. This positive attention will raise the company's stock price. In contrast, product recalls and data breaches may negatively influence a company's stock prices.Halozyme Therapeutics Stock Risk Measures
Given the investment horizon of 90 days the coefficient of variation of Halozyme Therapeutics is -890.24. The daily returns are distributed with a variance of 13.8 and standard deviation of 3.72. The mean deviation of Halozyme Therapeutics is currently at 2.38. For similar time horizon, the selected benchmark (Dow Jones Industrial) has volatility of 0.75
α | Alpha over Dow Jones | -0.5 | |
β | Beta against Dow Jones | 1.51 | |
σ | Overall volatility | 3.72 | |
Ir | Information ratio | -0.13 |
Halozyme Therapeutics Stock Return Volatility
Halozyme Therapeutics historical daily return volatility represents how much of Halozyme Therapeutics stock's daily returns swing around its mean - it is a statistical measure of its dispersion of returns. The firm inherits 3.7155% risk (volatility on return distribution) over the 90 days horizon. By contrast, Dow Jones Industrial accepts 0.7668% volatility on return distribution over the 90 days horizon. Performance |
| Timeline |
About Halozyme Therapeutics Volatility
Volatility is a rate at which the price of Halozyme Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Halozyme Therapeutics may increase or decrease. In other words, similar to Halozyme's beta indicator, it measures the risk of Halozyme Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of Halozyme Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.| Last Reported | Projected for Next Year | ||
| Selling And Marketing Expenses | 315.00 | 588.40 | |
| Market Cap | 1.9 B | 2 B |
Halozyme Therapeutics' stock volatility refers to the amount of uncertainty or risk involved with the size of changes in its stock's price. It is a statistical measure of the dispersion of returns on Halozyme Stock over a specified period of time, often expressed as the standard deviation of daily returns. In other words, it measures how much Halozyme Therapeutics' price varies over time.
3 ways to utilize Halozyme Therapeutics' volatility to invest better
Higher Halozyme Therapeutics' stock volatility means that the price of its stock is changing rapidly and unpredictably, while lower stock volatility indicates that the price of Halozyme Therapeutics stock is relatively stable. Investors and traders use stock volatility as an indicator of risk and potential reward, as stocks with higher volatility can offer the potential for more significant returns but also come with a greater risk of losses. Halozyme Therapeutics stock volatility can provide helpful information for making investment decisions in the following ways:- Measuring Risk: Volatility can be used as a measure of risk, which can help you determine the potential fluctuations in the value of Halozyme Therapeutics investment. A higher volatility means higher risk and potentially larger changes in value.
- Identifying Opportunities: High volatility in Halozyme Therapeutics' stock can indicate that there is potential for significant price movements, either up or down, which could present investment opportunities.
- Diversification: Understanding how the volatility of Halozyme Therapeutics' stock relates to your other investments can help you create a well-diversified portfolio of assets with varying levels of risk.
Halozyme Therapeutics Investment Opportunity
Halozyme Therapeutics has a volatility of 3.72 and is 4.83 times more volatile than Dow Jones Industrial. 33 percent of all equities and portfolios are less risky than Halozyme Therapeutics. You can use Halozyme Therapeutics to protect your portfolios against small market fluctuations. The stock experiences a normal downward trend and little activity. Check odds of Halozyme Therapeutics to be traded at $45.24 in 90 days.Weak diversification
The correlation between Halozyme Therapeutics and DJI is 0.31 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Halozyme Therapeutics Additional Risk Indicators
The analysis of Halozyme Therapeutics' secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in Halozyme Therapeutics' investment and either accepting that risk or mitigating it. Along with some common measures of Halozyme Therapeutics stock's risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (999.20) | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.33 | |||
| Information Ratio | (0.13) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential stocks, we recommend comparing similar stocks with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Halozyme Therapeutics Suggested Diversification Pairs
Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against Halozyme Therapeutics as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. Halozyme Therapeutics' systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, Halozyme Therapeutics' unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to Halozyme Therapeutics.
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.